

Condoms**Section**

Barrier methods

◦ -

Indications

Contact with health services for contraceptive management

Copper-containing intrauterine device**Section**

Intrauterine devices

◦ -

Indications

Contact with health services for insertion of contraceptive device

Diaphragms**Section**

Barrier methods

◦ -

Indications

Contact with health services for contraceptive management

Estradiol cypionate + medroxyprogesterone acetate**Section**

Injectable hormonal contraceptives

◦ Parenteral > General injections > IM: 5 mg + 25 mg

Indications

Contact with health services for reasons associated with reproduction

Ethinylestradiol + etonogestrel**Section**

Intravaginal contraceptives

◦ Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg

Indications

Contact with health services for contraceptive management

Ethinylestradiol + levonorgestrel**Section**

Oral hormonal contraceptives

◦ Oral > Solid: 50 µg + 250 µg [4]

◦ Oral > Solid: 30 µg + 150 µg

Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

Ethinylestradiol + norethisterone

Section

Oral hormonal contraceptives

- Oral > Solid: 35 µg + 1 mg

Indications

Contact with health services for contraceptive management

Etonogestrel-releasing implant

Section

Implantable contraceptives

- Implant > Subdermal: 68 mg single rod

Indications

Contact with health services for insertion of contraceptive device

Levonorgestrel

Section

Oral hormonal contraceptives

- Oral > Solid: 750 µg [2]; 1.5 mg [1]
- Oral > Solid: 30 µg

Intrauterine devices

- Intrauterine system with reservoir containing 52 mg of levonorgestrel.

Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

Contact with health services for insertion of contraceptive device

Levonorgestrel-releasing implant

Section

Implantable contraceptives

- Implant > Subdermal: 75 mg per rod (two-rods)

Indications

Contact with health services for insertion of contraceptive device

Medroxyprogesterone acetate

Section

Injectable hormonal contraceptives

- Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
- Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system

Indications

Contact with health services for reasons associated with reproduction

Norethisterone

Section

Oral hormonal contraceptives

- Oral > Solid: 350 µg

Indications

Contact with health services for contraceptive management

Norethisterone enantate

Section

Injectable hormonal contraceptives

- Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution

Indications

Contact with health services for reasons associated with reproduction

Progesterone vaginal ring

Section

Intravaginal contraceptives

- Local > Vaginal > vaginal ring: 2.074 g micronized progesterone

Indications

Contact with health services for contraceptive management

Ulipristal

Section

Oral hormonal contraceptives

- Oral > Solid: 30 mg tablet (ulipristal acetate)

Indications

Contact with health services for postcoital contraception